

University of Groningen

Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma

Zuur, L.; Vos, J. L.; Elbers, J. B.; Krijgsman, O.; Qiao, X.; van der Leun, A.; Smit, L.; van den Brekel, M. W.; Tan, B.; Jasperse, B.

Published in:
Annals of Oncology

DOI:
[10.1016/j.annonc.2020.08.2270](https://doi.org/10.1016/j.annonc.2020.08.2270)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Zuur, L., Vos, J. L., Elbers, J. B., Krijgsman, O., Qiao, X., van der Leun, A., Smit, L., van den Brekel, M. W., Tan, B., Jasperse, B., Vogel, W. V., Willems, S. M., Al-Mamgani, A., Peeper, D., Schumacher, T. N., Blank, C. U., de Boer, J. P., & Haanen, J. B. A. G. (2020). Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. *Annals of Oncology*, 31(Suppl. 4), S1169. <https://doi.org/10.1016/j.annonc.2020.08.2270>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LBA40 **Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial**

L. Zuur¹, J.L. Vos¹, J.B. Elbers², O. Krijgsman³, X. Qiao⁴, A. van der Leun⁵, L. Smit⁶, M.W. van den Brekel¹, B. Tan⁷, B. Jasperse⁸, W.V. Vogel⁹, S.M. Willems¹⁰, A. Al-Mamgani¹¹, D. Peeper³, T.N. Schumacher⁵, C.U. Blank¹², J.P. de Boer¹², J.B.A.G. Haanen¹²

¹Head and Neck Oncology & Surgery, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ²Radiation Oncology, Erasmus University Medical Center, Rotterdam, Netherlands; ³Molecular Oncology & Immunology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ⁴Tumor Biology & Immunology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ⁵Molecular Oncology & Immunology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ⁶Pathology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ⁷Otorhinolaryngology & Head and Neck Surgery, Maastricht University Medical Center +, Maastricht, Netherlands; ⁸Radiology, Amsterdam UMC, Location VUmc, Amsterdam, Netherlands; ⁹Nuclear Medicine, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ¹⁰Pathology, University Medical Center Groningen, Groningen, Netherlands; ¹¹Radiation Oncology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; ¹²Medical Oncology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Background: Nivolumab (NIVO) alone or with ipilimumab (COMBO) immune checkpoint blockade (ICB) prior to curative surgery has shown promising results in multiple tumor types. We completed a phase Ib/II study with neoadjuvant NIVO or COMBO in resectable head and neck squamous cell carcinoma (HNSCC) and show safety, efficacy and correlative biomarker results.

Methods: 32 stage II-IVB HNSCC patients indicated for curative (salvage) surgery were treated with NIVO (240mg, weeks 1&3, N=6) or NIVO (240mg, weeks 1&3) + IPI (1mg/kg, week 1, N=26) prior to surgery in week 5. Imaging was performed at baseline and week 4. AEs were reported in terms of CTCAE. Pathological response (pR) was defined as % change in viable tumor cells from baseline to on-treatment; $\geq 90\%$ pR was considered (near-) complete response (pCR). WES and RNAseq were performed on paired tumor biopsies.

Results: 32 (31 HPV-negative) patients started treatment (stage II n=3, III n=8, IVA-B n=11, recurrent disease n=10). 6 patients included with recurrent disease had had previous (C)RT. 1 patient discontinued ICB after one course due to patient's preference. Surgery was not postponed in any patient. 3/32 patients did not undergo surgery: 1 due to unresectable PD and 2 due to reasons unrelated to ICB or disease. Grade 3-4 irAEs in 11/32 patients were well manageable. (Near-)pCR in the primary

tumor was seen in 9/29 evaluable patients (31%). Another 31% of patients had 20-89% pR. At 14 months median FU, RFS for patients with (near-)pCR was 100%, significantly better than patients with $<90\%$ pR ($p < 0.05$). Metabolic response assessment with FDG-PET (week 4) was able to identify (near-)pCRs. A baseline AID/APOBEC-associated tumor mutational profile was correlated with (near)pCR ($p < 0.05$). Finally, (near)pCR tumors were characterized by a decrease in hypoxia gene expression after ICB.

Conclusions: Neoadjuvant ICB was feasible in HNSCC and induced (near)pCR in 31% of evaluable patients at time of surgery, which was accompanied by 100% RFS. Baseline AID/APOBEC-related mutations, on-treatment FDG-PET and resolution of hypoxia need future validation to discover their potential role as biomarkers for (near)pCR after ICB in HNSCC.

Clinical trial identification: NCT03003637.

Legal entity responsible for the study: Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.

Funding: Bristol Myers-Squibb.

Disclosure: L. Zuur: Spouse/Financial dependant: Mosadex U.A.; Spouse/Financial dependant: Obvious Pharmaceuticals BV. M.W. van den Brekel: Research grant/Funding (institution), Travel/Accommodation/Expenses: ATOS Medical. S.M. Willems: Research grant/Funding (institution); Roche; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Nextcure. T.N. Schumacher: Full/Part-time employment: Kite Pharma; Leadership role: Kite Pharma; Shareholder/Stockholder/Stock options: AIMM Therapeutics; Shareholder/Stockholder/Stock options: Allogene; Shareholder/Stockholder/Stock options: Merus; Shareholder/Stockholder/Stock options: Kite Pharma; Shareholder/Stockholder/Stock options: Neon Therapeutics; Shareholder/Stockholder/Stock options: Neogene Therapeutics; Shareholder/Stockholder/Stock options: Scenic Biotech; Advisory/Consultancy: AIMM Therapeutics; Advisory/Consultancy: Allogene; Advisory/Consultancy: Merus; Advisory/Consultancy: Neon Therapeutics; Advisory/Consultancy: Neogene Therapeutics; Advisory/Consultancy: Scenic Biotech; Research grant/Funding (self): Merck KgGA; Research grant/Funding (self): MSD; Licensing/Royalties: Kite Pharma; Licensing/Royalties: Neon Therapeutics; Licensing/Royalties: Scenic Biotech; Licensing/Royalties: Immatics. C.U. Blank: Honoraria (self), Paid to the institute: BMS; Honoraria (self), Paid to the institute: MSD; Honoraria (self), Paid to the institute: Roche; Honoraria (self), Paid to the institute: Novartis; Honoraria (self), Paid to the institute: GSK; Honoraria (self), Paid to the institute: AZ; Honoraria (self), Paid to the institute: Pfizer; Honoraria (self), Paid to the institute: Lilly; Honoraria (self), Paid to the institute: Genmab; Honoraria (self), Paid to the institute: Pierre Fabre; Honoraria (self), Paid to CUB: Third Rock Ventures; Shareholder/Stockholder/Stock options: Uniti Cars; Shareholder/Stockholder/Stock options: Immagine BV; Research grant/Funding (self), Paid to the institute: BMS; Research grant/Funding (self), Paid to the institute: Novartis; Research grant/Funding (self), Paid to the institute: NanoString. J.P. de Boer: Advisory/Consultancy: MSD; Research grant/Funding (self), Paid to the institute: Merck KgGA; Travel/Accommodation/Expenses: MSD. J.B.A.G. Haanen: Shareholder/Stockholder/Stock options: Neogene Therapeutics; Research grant/Funding (institution): BMS; Research grant/Funding (institution): MSD; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Neon. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2020.08.2270>